Open Public Meeting

The Part A/B Open Public Meetings (formerly known as Open Draft Meeting) are scheduled by the Noridian Contractor Medical Director(s) of Noridian Healthcare Solutions – A/B Medicare Administrative Contractor (MAC). The open public meeting is to allow the public to submit information for Noridian's consideration in Medicare Local Coverage Determination (LCD) development. However, specific claims are not discussed during these meetings.

Presenters / Speakers

If you wish to make a presentation at this open meeting, contact Christine Burnside, Medical Policy Specialist, using the contact information provided below.

Due to time constraints, all presentations will be limited to ten (10) minutes, with an additional five (5) to ten (10) minutes allowed for discussion. Requests to present at the meeting and all final presentations must be submitted one (1) week prior to the event date. No changes to the presentation will be accepted after the one-week deadline. Note: Presentations will be sent to registrants prior to the meeting date.


Participate in one of two ways.

Registration is required. Select the "Register Now" link below.

  1. Attend in-person
    • Registration no later than one week prior to event. Space is limited. Only first 65 registrants will be allowed to attend in person. Please limit in-person participation requests to only those who will actively participate and contribute to the discussions.
  2. Attend via teleconference
    • Upon registration a telephone number, access code, and audio PIN will be provided to you. Do not share this information.
State Date Time (PT) In Person Location Teleconference Agenda Topics Transcript
All 05/30/19 11 a.m. Hampton Inn
1531 Pacific Highway
San Diego CA 92101
Register Now
  • MolDX: Next-Generation Sequencing for Solid Tumors
  • MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies
  • Lab: Drug Interaction Testing
  • MolDX: Guardant360® Plasma-Based Comprehensive Genomic Profiling in Solid Tumors
  • MolDX: Prospera
  • MolDX: TruGraf Blood Gene Expression Test
  • MolDX: Decipher® Biopsy Prostate Cancer Classifier Assay for Men with Unfavorable Intermediate Risk Disease
  • MolDX: Decipher® Biopsy Prostate Cancer Classifier Assay for Men with Favorable Intermediate Risk Disease Lumbar Spinal Fusion
  • MolDX: Pigmented Lesion Assay
All 06/04/19 11 a.m. LAX Marriott
5855 West Century Blvd
Los Angeles CA  90045
Register Now Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF) View [PDF]


Last Updated May 16, 2019